Sorry, you must have the wrong number http://www.cathypickens.com/online-service-writing-college-papers/ writing essay services  Alnylam CEO John Maraganore has rolled out the Phase I data on ALN-TTRsc ahead of the company's R&D day this morning in New York City, which provides the company a stage to tout a number of milestones in a hard-fought campaign to advance RNAi drugs into human studies. The human data have helped propel Alnylam's stock 192% over the past 12 months, well north of the 40% increase in the Nasdaq Biotechnology Index during the same period.